Fertility and Sterility
Volume 89, Issue 6 , Pages 1685-1693 , June 2008

Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization–intracytoplasmic sperm injection patients

  • Peter G.A. Hompes, M.D., Ph.D.

      Affiliations

    • Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    • Corresponding Author InformationReprint requests: Peter G. A. Hompes, M.D., Ph.D., Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands (FAX: 31-20-444-00-45).
    • ,
  • Frank J. Broekmans, M.D., Ph.D.

      Affiliations

    • University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • Diederik A. Hoozemans, M.D.

      Affiliations

    • Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    • ,
  • Roel Schats, M.D., Ph.D.

      Affiliations

    • Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    • ,
  • FIRM group

      Affiliations

    • FIRM = First IVF-ICSI Cycle Recombinant FSH vs. Menotropin.

Received 15 March 2007 ,Revised 23 May 2007 ,Accepted 23 May 2007.

References 

  1. Filicori M, Cognigni GE, Pocognoli P, Ciampaglia W, Bernardi S. Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab. 2003;14:267–273
  2. Fleming R, Chung CC, Yates RW, Coutts JR. Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum Reprod. 1996;11:1854–1858
  3. Gordon UD, Harrison RF, Fawzy M, Hennelly B, Gordon AC. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril. 2001;75:324–331
  4. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15:1003–1008
  5. Balasch J, Miro F, Burzaco I, Casamitjana R, Civico S, Ballesca JL, et al. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod. 1995;10:1678–1683
  6. The European Recombinant Human LH Study Group . Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83:1507–1514
  7. Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2003;(1):CD003973
  8. European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone . Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78:520–528
  9. Kobayashi M, Nakano R, Ooshima A. Immunohistochemical localization of pituitary gonadotrophins and gonadal steroids confirms the “two-cell, two-gonadotrophin” hypothesis of steroidogenesis in the human ovary. J Endocrinol. 1990;126:483–488
  10. Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao Ch V, Tesarik J, et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril. 2005;84:275–284
  11. Platteau P, Andersen AN, Balen A, Devroey P, Sorensen P, Helmgaard L, et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod. 2006;21:1798–1804
  12. Wolfenson C, Groisman J, Couto AS, Hedenfalk M, Cortvrindt RG, Smitz JE, et al. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online. 2005;10:442–454
  13. Stokman PG, de Leeuw R, van den Wijngaard HA, Kloosterboer HJ, Vemer HM, Sanders AL. Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil Steril. 1993;60:175–178
  14. Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005;84:394–401
  15. Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Spettoli D, Taraborrelli S, et al. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration. Hum Reprod. 2002;17:2009–2015
  16. Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril. 2001;76:543–549
  17. Kilani Z, Dakkak A, Ghunaim S, Cognigni GE, Tabarelli C, Parmegiani L, et al. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod. 2003;18:1194–1199
  18. Arce JC, Nyboe Andersen A, Collins J. Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review. Hum Reprod. 2005;20:1757–1771
  19. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21:3217–3227
  20. Platteau P, Smitz J, Albano C, Sorensen P, Arce JC, Devroey P. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril. 2004;81:1401–1404
  21. Assou S, Anahory T, Pantesco V, Carrour TL, Pellestor F, Klein B, et al. The human cumulus-oocyte complex gene-expression profile. Hum Reprod. 2006;21:1705–1719
  22. Weston AM, Zelinski-Wooten MB, Hutchison JS, Stouffer RL, Wolf DP. Developmental potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone. Hum Reprod. 1996;11:608–613
  23. Smitz J, Andersen AN, Devroey P, Arce JC, Merit Group . Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinat FSH in IVF patients. Hum Reprod. 2007;22:676–687

 The research institutes of the participating centers were supported by Ferring BV, Hoofddorp, The Netherlands. P.G.A.H. has conducted clinical research sponsored by Abbott, Ferring, Organon, Schering, and Serono. F.J.B. has conducted clinical research sponsored by Wyeth, Ferring, Organon, and Serono.

PII: S0015-0282(07)01207-1

doi: 10.1016/j.fertnstert.2007.05.039

Fertility and Sterility
Volume 89, Issue 6 , Pages 1685-1693 , June 2008

Article Tools

* Image Usage & Resolution